Environmental, Social and Governance Report

The report describes Sino Biopharmaceutical's 2023 ESG performance across climate, people and governance. The company reported a 13% reduction in GHG emission intensity from 2021 and renewable energy consumption of 7,504 MWh. It also reported 25,880 employees and a 100% workplace safety and occupational health training coverage rate. An independent assurance opinion by the British Standards Institution covered the report's sustainability disclosures and key performance indicators.